Abstract:Programmed cell death (PD-1) and programmed cell death ligand 1 (PD-L1) inhibitors have been increasingly used in cancer therapy. Understanding the treatment-related adverse events of these drugs is critical for clinical practice.To evaluate the incidences of treatment-related adverse events of PD-1 and PD-L1 inhibitors and the differences between different drugs and cancer types.PubMed, Web of Science, Embase, and Scopus were searched from October 1, 2017, through December 15, 2018.Published clinical trials on single-agent PD-1 and PD-L1 inhibitors with tabulated data on treatment-related adverse events were included.Trial name, phase, cancer type, PD-1 and PD-L1 inhibitor used, dose escalation, dosing schedule, number of patients, number of all adverse events, and criteria for adverse event reporting data were extracted from each included study, and bayesian multilevel regression models were applied for data analysis.Incidences of treatment-related adverse events and differences between different drugs and cancer types.This systematic review and meta-analysis included 125 clinical trials involving 20 128 patients; 12 277 (66.0%) of 18 610 patients from 106 studies developed at least 1 adverse event of any grade (severity), and 2627 (14.0%) of 18 715 patients from 110 studies developed at least 1 adverse event of grade 3 or higher severity. The most common all-grade adverse events were fatigue (18.26%; 95% CI, 16.49%-20.11%), pruritus (10.61%; 95% CI, 9.46%-11.83%), and diarrhea (9.47%; 95% CI, 8.43%-10.58%). The most common grade 3 or higher adverse events were fatigue (0.89%; 95% CI, 0.69%-1.14%), anemia (0.78%; 95% CI, 0.59%-1.02%), and aspartate aminotransferase increase (0.75%; 95% CI, 0.56%-0.99%). Hypothyroidism (6.07%; 95% CI, 5.35%-6.85%) and hyperthyroidism (2.82%; 95% CI, 2.40%-3.29%) were the most frequent all-grade endocrine immune-related adverse events. Nivolumab was associated with higher mean incidences of all-grade adverse events compared with pembrolizumab (odds ratio [OR], 1.28; 95% CI, 0.97-1.79) and grade 3 or higher adverse events (OR, 1.30; 95% CI, 0.89-2.00). PD-1 inhibitors were associated with a higher mean incidence of grade 3 or higher adverse events compared with PD-L1 inhibitors (OR, 1.58; 95% CI, 1.00-2.54).Different PD-1 and PD-L1 inhibitors appear to have varying treatment-related adverse events; a comprehensive summary of the incidences of treatment-related adverse events in clinical trials provides an important guide for clinicians.

Current Status of PD-1/PD-L1 Anti-tumor Therapy and Exploration of the Mechanism of Immune-related Adverse Events

Research Status and Outlook of PD-1/PD-L1 Inhibitors for Cancer Therapy

Advances of PD-1/PD-L1 inhibitors in tumor immunotherapy

Research progress of anti-PD-1 / PD-L1 immunotherapy biomarkers

PD-1/PD-L1 Inhibitor - Related Adverse Events and Their Management in Breast Cancer

PD-1/PD-L1 Checkpoint Inhibitors in Tumor Immunotherapy

The role of PD-1/PD-L1 and application of immune-checkpoint inhibitors in human cancers

Research progress of therapeutic effects and drug resistance of immunotherapy based on PD-1/PD-L1 blockade

Application of PD-1 Blockade in Cancer Immunotherapy

Research progress of tumor targeted drug delivery based on PD-1/PD-L1

Immune Checkpoint Blockade in Cancer Immunotherapy: Mechanisms, Clinical Outcomes, and Safety Profiles of PD-1/PD-L1 Inhibitors

Treatment of Patients with Cancer Using PD‑1/PD‑L1 Antibodies: Adverse Effects and Management Strategies (Review).

Clinical evaluation of compounds targeting PD-1/PD-L1 pathway for cancer immunotherapy

PD-1 regulation in immune homeostasis and immunotherapy

Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials

PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations

Advances in pharmacokinetics and pharmacodynamics of PD-1/PD-L1 inhibitors

Future of anti-PD-1/PD-L1 applications: Combinations with other therapeutic regimens

PD-1/PD-L1 pathway: current researches in cancer.

Anti-tumor immune therapy with programmed death-1 and its ligand inhibitors:research advances

PD-1/PD-Ls SignaI Pathway and the Appiication of Anti-Pd-1/pd-ls Antibodies in Cancer Therapy